Pioglitazone attenuates cystic burden in the PCK rodent model of polycystic kidney disease

Bonnie L. Blazer-Yost, Julie Haydon, Tracy Eggleston-Gulyas, Jey Hsin Chen, Xiaofang Wang, Vincent Gattone, Vicente Torres

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Polycystic kidney disease (PKD) is a genetic disorder characterized by growth of fluid-filled cysts predominately in kidney tubules and liver bile ducts. Currently, the clinical management of PKD is limited to cyst aspiration, surgical resection or organ transplantation. Based on an observation that PPARγ agonists such as pioglitazone and rosiglitazone decrease mRNA levels of a Cl- transport protein, CFTR (cystic fibrosis transmembrane conductance regulator), and the Cl- secretory response to vasopressin in cultured renal cells, it is hypothesized that PPARγ agonists will inhibit cyst growth. The current studies show that a 7- or 14-week pioglitazone feeding regimen inhibits renal and hepatic bile duct cyst growth in the PCK rat, a rodent model orthologous to human PKD. These studies provide proof of concept for the mechanism of action of the PPARγ agonists and suggest that this class of drugs may be effective in controlling both renal and hepatic cyst growth and fibrosis in PKD.

Original languageEnglish (US)
Article number274376
JournalPPAR Research
DOIs
StatePublished - 2010

Fingerprint

pioglitazone
Polycystic Kidney Diseases
Peroxisome Proliferator-Activated Receptors
Rodentia
Cysts
rosiglitazone
Growth
Kidney
Kidney Tubules
Choledochal Cyst
Cyst Fluid
Common Hepatic Duct
Cystic Fibrosis Transmembrane Conductance Regulator
Inborn Genetic Diseases
Liver
Organ Transplantation
Bile Ducts
Vasopressins
Cultured Cells
Carrier Proteins

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Drug Discovery

Cite this

Blazer-Yost, B. L., Haydon, J., Eggleston-Gulyas, T., Chen, J. H., Wang, X., Gattone, V., & Torres, V. (2010). Pioglitazone attenuates cystic burden in the PCK rodent model of polycystic kidney disease. PPAR Research, [274376]. https://doi.org/10.1155/2010/274376

Pioglitazone attenuates cystic burden in the PCK rodent model of polycystic kidney disease. / Blazer-Yost, Bonnie L.; Haydon, Julie; Eggleston-Gulyas, Tracy; Chen, Jey Hsin; Wang, Xiaofang; Gattone, Vincent; Torres, Vicente.

In: PPAR Research, 2010.

Research output: Contribution to journalArticle

Blazer-Yost BL, Haydon J, Eggleston-Gulyas T, Chen JH, Wang X, Gattone V et al. Pioglitazone attenuates cystic burden in the PCK rodent model of polycystic kidney disease. PPAR Research. 2010. 274376. https://doi.org/10.1155/2010/274376
Blazer-Yost, Bonnie L. ; Haydon, Julie ; Eggleston-Gulyas, Tracy ; Chen, Jey Hsin ; Wang, Xiaofang ; Gattone, Vincent ; Torres, Vicente. / Pioglitazone attenuates cystic burden in the PCK rodent model of polycystic kidney disease. In: PPAR Research. 2010.
@article{46607ff823f049cebad41ca48d36068b,
title = "Pioglitazone attenuates cystic burden in the PCK rodent model of polycystic kidney disease",
abstract = "Polycystic kidney disease (PKD) is a genetic disorder characterized by growth of fluid-filled cysts predominately in kidney tubules and liver bile ducts. Currently, the clinical management of PKD is limited to cyst aspiration, surgical resection or organ transplantation. Based on an observation that PPARγ agonists such as pioglitazone and rosiglitazone decrease mRNA levels of a Cl- transport protein, CFTR (cystic fibrosis transmembrane conductance regulator), and the Cl- secretory response to vasopressin in cultured renal cells, it is hypothesized that PPARγ agonists will inhibit cyst growth. The current studies show that a 7- or 14-week pioglitazone feeding regimen inhibits renal and hepatic bile duct cyst growth in the PCK rat, a rodent model orthologous to human PKD. These studies provide proof of concept for the mechanism of action of the PPARγ agonists and suggest that this class of drugs may be effective in controlling both renal and hepatic cyst growth and fibrosis in PKD.",
author = "Blazer-Yost, {Bonnie L.} and Julie Haydon and Tracy Eggleston-Gulyas and Chen, {Jey Hsin} and Xiaofang Wang and Vincent Gattone and Vicente Torres",
year = "2010",
doi = "10.1155/2010/274376",
language = "English (US)",
journal = "PPAR Research",
issn = "1687-4757",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Pioglitazone attenuates cystic burden in the PCK rodent model of polycystic kidney disease

AU - Blazer-Yost, Bonnie L.

AU - Haydon, Julie

AU - Eggleston-Gulyas, Tracy

AU - Chen, Jey Hsin

AU - Wang, Xiaofang

AU - Gattone, Vincent

AU - Torres, Vicente

PY - 2010

Y1 - 2010

N2 - Polycystic kidney disease (PKD) is a genetic disorder characterized by growth of fluid-filled cysts predominately in kidney tubules and liver bile ducts. Currently, the clinical management of PKD is limited to cyst aspiration, surgical resection or organ transplantation. Based on an observation that PPARγ agonists such as pioglitazone and rosiglitazone decrease mRNA levels of a Cl- transport protein, CFTR (cystic fibrosis transmembrane conductance regulator), and the Cl- secretory response to vasopressin in cultured renal cells, it is hypothesized that PPARγ agonists will inhibit cyst growth. The current studies show that a 7- or 14-week pioglitazone feeding regimen inhibits renal and hepatic bile duct cyst growth in the PCK rat, a rodent model orthologous to human PKD. These studies provide proof of concept for the mechanism of action of the PPARγ agonists and suggest that this class of drugs may be effective in controlling both renal and hepatic cyst growth and fibrosis in PKD.

AB - Polycystic kidney disease (PKD) is a genetic disorder characterized by growth of fluid-filled cysts predominately in kidney tubules and liver bile ducts. Currently, the clinical management of PKD is limited to cyst aspiration, surgical resection or organ transplantation. Based on an observation that PPARγ agonists such as pioglitazone and rosiglitazone decrease mRNA levels of a Cl- transport protein, CFTR (cystic fibrosis transmembrane conductance regulator), and the Cl- secretory response to vasopressin in cultured renal cells, it is hypothesized that PPARγ agonists will inhibit cyst growth. The current studies show that a 7- or 14-week pioglitazone feeding regimen inhibits renal and hepatic bile duct cyst growth in the PCK rat, a rodent model orthologous to human PKD. These studies provide proof of concept for the mechanism of action of the PPARγ agonists and suggest that this class of drugs may be effective in controlling both renal and hepatic cyst growth and fibrosis in PKD.

UR - http://www.scopus.com/inward/record.url?scp=78650772659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650772659&partnerID=8YFLogxK

U2 - 10.1155/2010/274376

DO - 10.1155/2010/274376

M3 - Article

C2 - 21052534

AN - SCOPUS:78650772659

JO - PPAR Research

JF - PPAR Research

SN - 1687-4757

M1 - 274376

ER -